Candiduria Treatment
Most patients with candiduria should NOT receive antifungal treatment, as candiduria typically represents colonization rather than infection—the critical first step is removing the urinary catheter if present, which alone resolves candiduria in approximately 50% of cases. 1
When NOT to Treat (Most Common Scenario)
Antifungal therapy is NOT recommended for asymptomatic candiduria unless the patient falls into specific high-risk categories 1. The 2016 IDSA guidelines emphasize this strongly, as most candiduria represents benign colonization that resolves spontaneously, particularly after catheter removal 1, 2.
Key action: Remove indwelling bladder catheters whenever feasible—this is the single most important intervention 1.
High-Risk Patients Who REQUIRE Treatment
Treatment is indicated ONLY for:
- Neutropenic patients (treat as candidemia) 1
- Very low-birth-weight infants <1500g (treat as candidemia) 1
- Patients undergoing urologic procedures (treat prophylactically) 1
- Symptomatic patients with cystitis or pyelonephritis 1
Treatment Regimens by Clinical Scenario
For Symptomatic Cystitis (Fluconazole-Susceptible Species)
- Oral fluconazole 200 mg (3 mg/kg) daily for 2 weeks 1
- This is a strong recommendation with moderate-quality evidence
- Remove catheter if present (strongly recommended) 1
For Fluconazole-Resistant C. glabrata Cystitis
- Amphotericin B deoxycholate 0.3–0.6 mg/kg daily for 1–7 days OR
- Oral flucytosine 25 mg/kg 4 times daily for 7–10 days 1
- Alternative: Amphotericin B bladder irrigation (50 mg/L sterile water daily for 5 days) may be useful 1
For C. krusei Cystitis
- Amphotericin B deoxycholate 0.3–0.6 mg/kg daily for 1–7 days 1
For Symptomatic Pyelonephritis (Fluconazole-Susceptible)
- Oral fluconazole 200–400 mg (3–6 mg/kg) daily for 2 weeks 1
- Eliminate urinary tract obstruction (strongly recommended) 1
- Consider removing/replacing nephrostomy tubes or stents if present 1
For Pyelonephritis with Fluconazole-Resistant C. glabrata
- Amphotericin B deoxycholate 0.3–0.6 mg/kg daily for 1–7 days with or without oral flucytosine 25 mg/kg 4 times daily 1
- Alternative: Flucytosine monotherapy 25 mg/kg 4 times daily for 2 weeks (weaker recommendation) 1
For Patients Undergoing Urologic Procedures (Prophylaxis)
- Oral fluconazole 400 mg (6 mg/kg) daily OR
- Amphotericin B deoxycholate 0.3–0.6 mg/kg daily
- Give for several days before AND after the procedure 1
Critical Pitfalls to Avoid
Do not use echinocandins or azoles other than fluconazole for candiduria—they achieve inadequate urinary concentrations and are ineffective 3, 2. This is a common error in practice.
Avoid unnecessary treatment: Recent real-world data show that 31.3% of patients receiving antifungal therapy for candiduria were treated unnecessarily 4. While guideline adherence was high (84-85%), overtreatment remains problematic 5, 4.
Beware of fluconazole resistance: The emergence of fluconazole-resistant species, particularly C. glabrata and Candidozyma auris, is increasing, especially in patients with prior antifungal exposure 6, 4. Always obtain susceptibility testing when treating candiduria 1.
Special Considerations
Recurrence is common: Even when fluconazole initially eradicates candiduria, long-term eradication rates are disappointing, with similar candiduria rates at 2 weeks post-treatment between treated and untreated patients 7. This reinforces that treatment should be reserved for high-risk or symptomatic patients only.
Intravesical amphotericin B shows promise for fluconazole-resistant candiduria (particularly C. glabrata) with good efficacy (66% eradication) and minimal nephrotoxicity 8, though this remains a specialized intervention.
Mortality impact: Treatment of asymptomatic candiduria does not reduce mortality or improve clinical outcomes, even in high-risk populations like kidney transplant recipients 9. However, unnecessary treatment may increase multidrug-resistant organism colonization 9.